Abstract
Cardiovascular diseases (CVDs), the main cause of death worldwide, can only be prevented, diagnosed, and managed more effectively by integrating digital tools, biomarkers, and improved diagnostics. Traditional methods often fail to address the complexity of these diseases; therefore, innovative approaches are required to improve patient outcomes. This review highlights recent developments, clinical consequences, and integration issues as it examines the revolutionary role of digital health technology, biomarkers, and artificial intelligence (AI)-driven imaging in cardiovascular care. A thorough review of the literature focused on cardiovascular biomarkers, imaging techniques, and digital technologies. Modern CVD management revolves around precision medicine, multiomics methods, and AI-driven diagnostics. AI-driven imaging has improved patient classification and diagnostic accuracy. Examples of this include cardiac magnetic resonance imaging and hybrid positron emission tomography/computed tomography. Early identification and risk assessment are facilitated by novel biomarkers, including high-sensitivity troponins and inflammatory markers. Digital technologies, including wearables and telemedicine, enhance patient monitoring and adherence. The personalization of therapy and risk prediction has been greatly enhanced by the combination of AI and machine learning. Digital health technologies, AI-driven imaging, and biomarker integration are transforming cardiovascular care by facilitating early diagnosis, accurate therapy, and individualized management. Nevertheless, for broad acceptance, issues with accessibility, affordability, and ethics must be resolved. Interdisciplinary cooperation should be a key component of future research to guarantee the smooth incorporation of cutting-edge technology into standard clinical practice, which will ultimately improve cardiovascular health outcomes worldwide.
Introduction
According to the World Health Organization, cardiovascular diseases (CVDs) continue to be the leading cause of death globally, accounting for more than 17.9 million deaths each year. Traditional methods sometimes fall short of addressing the complexity and heterogeneity inherent in CVDs, even with notable advances in pharmacotherapy and interventional techniques. The enduring worldwide burden of these diseases is a result of issues such as inadequate preventative measures, delayed diagnosis, and a lack of individualized care.
In recent years, the integration of cutting-edge technologies has begun to transform the landscape of cardiovascular care. The development of artificial intelligence (AI) has opened new avenues for cardiovascular imaging analysis and interpretation. Particularly in modalities such as cardiac magnetic resonance imaging and echocardiography, AI-driven applications have shown promise in improving the precision and effectiveness of image-based diagnosis.1,2 For example, AI algorithms have been created to automate the segmentation of cardiac structures, which makes it easier to evaluate heart function and identify diseases with a high level of accuracy. These advancements streamline diagnostics and reduce interobserver variability, resulting in more consistent and reliable assessments. 3
In the diagnosis, prognosis, and treatment of CVDs, biomarkers remain essential. 4 Conventional biomarkers for myocardial damage and heart failure (HF) are well established in clinical practice and include cardiac troponins and natriuretic peptides, respectively. 5 Novel markers of inflammation, fibrosis, and metabolic abnormalities, all of which are essential to the pathogenesis of numerous cardiovascular disorders, have been added to the repertoire of biomarkers identified in recent studies. Clinicians can track disease development more precisely, customize treatment therapies, and stratify risk using these biomarkers. 5
Wearable technology and telemedicine platforms are examples of digital tools that have become invaluable resources for the ongoing monitoring and treatment of patients with CVDs. 6 Vital signs, physical activity, and other health measurements can be tracked in real time with wearable technology, providing patients and medical professionals with useful information. Early adverse event detection, treatment regimen adherence, and customized lifestyle changes are all facilitated by this ongoing monitoring. By facilitating remote consultations, prompt therapy modifications, and enhanced patient engagement—especially among marginalized populations—telemedicine has further increased access to cardiovascular care. 7
The combination of digital health tools, biomarkers, and sophisticated imaging techniques represents a paradigm change toward more specialized and customized cardiovascular care. Health care systems can adopt proactive approaches that prioritize early identification, prevention, and individualized management plans in place of the conventional reactive methods of therapy by utilizing these advancements (Fig. 1). This comprehensive approach has the potential to improve patient outcomes globally by lowering the incidence and impact of CVDs. To improve cardiovascular health care, this review focuses on the revolutionary relevance of biomarkers, AI-driven imaging technology, and digital health tools. Building on this framework, the following sections explore recent advancements in diagnostics that use these cutting-edge tools to address critical gaps in cardiovascular treatment.
Enhancing cardiovascular outcomes through technological advancements: A conceptual flowchart. This flowchart presents a comprehensive visualization of how the integration of biomarkers, artificial intelligence (AI)-driven imaging, and digital health tools synergistically improves cardiovascular health care outcomes. It describes a simplified process from early diagnosis with AI-driven imaging and multiomics biomarkers to customized treatments with precision medications and regenerative therapies. Additionally, illustrated is the use of digital technologies such as wearables and smartphone apps in monitoring and prevention. Predictive analytics and big data round out the feedback loop, enabling ongoing care improvement. Overall, the graphic highlights how the use of new, linked health care technologies is driving a move toward proactive, patient-centered cardiovascular treatment.
Advances in Cardiovascular Diagnostics
The ability to see and evaluate heart structures and functions with remarkable accuracy has been greatly improved by recent developments in cardiovascular diagnostics.
Identification of biomarkers
CVD prognosis and early detection depend heavily on biomarkers. Our knowledge of these biomarkers has greatly increased as a result of recent developments in multiomics techniques, which have also produced new indicators and a better understanding of disease mechanisms. 8
Troponins with high sensitivity
Because cardiac troponins have high specificity for heart damage, they have historically been the mainstays for diagnosing myocardial infarction (MI). This diagnostic procedure has been completely transformed by the creation of high-sensitivity troponin assays, which allow for the preclinical diagnosis of myocardial damage. By detecting even the smallest increases in troponin levels, these assays help detect cardiac injury before clinical symptoms appear. Improving patient outcomes and starting therapies in a timely manner depend on early detection.
Galectin-3 and soluble ST2
The development of HF is a complicated process that is impacted by a number of different molecular pathways. Galectin-3 is a lectin that binds β-galactosidase and has become a prognostic marker for HF. Cardiac fibrosis is driven by fibroblast proliferation and collagen deposition, leading to ventricular remodeling and dysfunction. In individuals with HF, higher levels of galectin-3 have been linked to worse outcomes. Likewise, cardiac stress and fibrosis are reflected by soluble ST2, a member of the interleukin-1 receptor family. Since elevated levels of soluble ST2 are associated with a poor prognosis in HF patients, they are important biomarkers for risk assessment.
Integration of multiomics
The complex relationships among genes, proteins, metabolites, and environmental variables are all part of the pathophysiology of CVD. The integration of data from proteomics, metabolomics, genomics, and other omics disciplines has become essential for deciphering this complexity.9,10 A thorough grasp of disease pathways is made possible by this all-encompassing strategy, sometimes referred to as multiomics integration. For example, regulatory networks and pathways that are dysregulated in CVD can be identified by integrating transcriptome and proteomic profiles with genomic data. These results are further supported by metabolomic analysis, which revealed changes in metabolic pathways linked to disease states.11,12 Precision diagnostics and personalized treatment in cardiology have been made possible by the discovery of new biomarkers and therapeutic targets as a result of these integrative analyses. 11
In summary, the identification and verification of biomarkers via sophisticated multiomics techniques have greatly improved our ability to identify and treat cardiovascular disorders early in life. In HF, biomarkers such as soluble ST2 and galectin-3 have predictive value, whereas high-sensitivity troponins help detect subclinical myocardial injury. The creation of focused treatment plans and better patient care is made possible by the integration of various omics data, which offers a thorough understanding of the molecular foundations of CVDs.
Advanced imaging technique
Advances in imaging technologies have enabled physicians to observe intricate details of the anatomy and physiology of the heart, which has revolutionized the diagnosis and treatment of cardiovascular disorders.
Three-dimensional and four-dimensional echocardiography
By allowing real-time visualization of the heart’s dynamic processes, these echocardiography techniques have transformed cardiac imaging. These techniques are very useful for detecting valvular diseases and complicated congenital cardiac defects. Capturing the motion of the heart in several planes improves the precision of anatomical evaluations and directs treatment. According to studies, 3D echocardiography offers thorough imaging of moving cardiovascular components, opening the door for 4D datasets that provide real-time heart function insights.13,14
Magnetic resonance imaging of the heart
A key component of noninvasive cardiac diagnostics, cardiac magnetic resonance imaging (MRI) provides a thorough picture of the properties of myocardial tissue. By incorporating AI algorithms into cardiac MR images, myocardial fibrosis and perfusion anomalies can now be more accurately quantified, improving the diagnostic accuracy for ischemic heart diseases. Early and more accurate diagnosis may result from AI-driven analysis of cine cardiac MRI data, which has demonstrated promise in identifying minor myocardial texture changes suggestive of fibrosis. 15
Hybrid imaging modalities
Positron emission tomography/computerized tomography and single-photon emission computed tomography/computerized tomography are two examples of hybrid modalities that combine metabolic and anatomical imaging. These modalities have become potent tools in cardiovascular diagnostics. By integrating structural and functional data, these methods offer a thorough evaluation that is essential for determining the sensitivity of atherosclerotic plaques and directing treatment plans. A more comprehensive understanding of atherosclerosis and its possible therapeutic implications is made possible by hybrid imaging, which provides information on the morphological characteristics of plaques as well as their metabolic activity.
In summary, the accuracy and thoroughness of cardiovascular diagnosis have significantly increased with the use of cutting-edge imaging techniques, such as 3D/4D echocardiography, AI-driven cardiac MRI, and hybrid imaging modalities. These developments are essential for creating patient-specific therapy regimens in addition to helping with the precise identification and description of cardiac disorders.
Using AI and machine learning to predict risk
Cardiovascular risk prediction is being revolutionized by AI and machine learning (ML), which are improving the accuracy of current models and providing new diagnostic tools. Estimating cardiovascular risk has traditionally relied on conventional risk assessment techniques, such as the Framingham risk score. The static nature of the data they use, however, limits their capacity for prediction.
AI-driven models are able to process enormous volumes of real-time data from wearable technology, imaging studies, and electronic health records (EHRs), enabling more dynamic and customized risk evaluations.
The superiority of AI-based models over conventional statistical methods has been shown in recent studies. The application of ML algorithms to intraplaque neovascularization data and carotid ultrasonography features, for example, has improved the prediction of cardiovascular events and coronary artery disease. The AI-based approach demonstrated a notable improvement in predictive performance in a study that contrasted ML techniques with traditional statistical analyses, highlighting the potential of AI to improve cardiovascular risk assessments. 16
AI has advanced significantly in the interpretation of electrocardiograms (ECGs) beyond risk prediction. High-sensitivity and high-specificity ML techniques have been created to identify arrhythmias and QT interval prolongation. With an area under the curve of 0.90 and an overall accuracy of 83%, AI models have notably shown that they can distinguish atrial fibrillation from normal sinus rhythm ECGs. Early diagnosis and intervention are facilitated by the ability of these models to identify small abnormalities in ECG data that human doctors miss. 17
Advanced cardiac monitoring is now much more accessible because of the incorporation of AI into mobile health devices. The heart rate-corrected QT (QTc) interval is a crucial indicator for diseases such as long QT syndrome, and it can be precisely measured via AI-enabled mobile ECG devices. The AI model correctly predicted QTc intervals from mobile ECG tracings in a study using a deep neural network trained on more than 1.6 million 12-lead ECGs. 18 In situations where conventional 12-lead ECGs are not easily accessible, this development provides an affordable way to screen for both acquired and congenital long QT syndrome. 19
AI has also been used to identify latent long QT syndrome, a disease in which individuals are at risk for arrhythmias even though their resting QTc is normal. Even when the resting QTc was within normal ranges, a deep neural network model was able to differentiate between patients with disguised long QT syndrome and those without the disorder. This feature demonstrates how AI may be able to reveal hidden diseases that traditional diagnostic techniques could miss. 18
In summary, cardiovascular care is changing as a result of the use of AI and ML in cardiovascular risk assessment and screening. AI improves the precision of risk assessments and the accuracy of diagnostic interpretations by utilizing real-time data and sophisticated algorithms, which eventually results in better patient outcomes. With these diagnostic advancements in place, the emphasis now shifts to how these tools translate into more effective treatment strategies and improved management of CVDs.
Advances in Treatment and Management
The introduction of precision medicine has transformed cardiovascular care by shifting from generic to more customized treatments. Proprotein convertase subtilisin/kexin type 9 (PCSK9) and sodium—glucose cotransporter 2 (SGLT2) inhibitors, which provide focused benefits for particular patient populations, are two examples of this paradigm shift in action. 20
Precision medicine
The advent of precision medicine has brought about a change in health care practices from “one-size-fits-all” to customized care.
PCSK9 inhibitors
The creation of monoclonal antibodies that target the PCSK9 enzyme, known as PCSK9 inhibitors, is a prime example. Low-density lipoprotein cholesterol (LDL-C) levels are significantly reduced by these inhibitors, especially in patients who are resistant to or intolerant of statin therapy. Clinical studies have demonstrated that PCSK9 inhibitors lower the risk of major cardiovascular events, such as MI and stroke, in addition to lowering LDL-C. 21 For example, individuals treated with PCSK9 inhibitors experienced a significant decrease in cardiovascular events compared with those treated with a placebo, according to a meta-analysis that included several randomized controlled trials. 22
Monoclonal antibodies called evolocumab and alirocumab target PCSK9 and, when combined with statins, effectively lower LDL-C levels by approximately 60%. According to clinical trials, evolocumab lowers LDL-C and the risk of cardiovascular events in patients who already have atherosclerotic CVD. 23 For patients who need further LDL-C reduction due to clinical atherosclerotic CVD or heterozygous familial hypercholesterolemia, alirocumab has also been demonstrated to be effective in lowering LDL-C levels. 24
A new mechanism involves small interfering RNA (siRNA) treatment with inclisiran, which prevents the hepatic manufacture of PCSK9. Adults with primary hypercholesterolemia or mixed dyslipidemia can use inclisiran, which is approved for use every two years and has been demonstrated to significantly lower LDL-C levels.25,26
SGLT2 inhibitors
The use of SGLT2 inhibitors for new purposes are another noteworthy development in precision medicine. SGLT2 inhibitors, which were first created to help manage blood sugar levels in people with type 2 diabetes (T2D), have shown impressive cardiovascular advantages. Research has shown that these medications, regardless of a patient’s diabetes condition, dramatically lower the likelihood of HF hospitalization and enhance cardiac function in HF patients. 27 According to a systematic analysis, SGLT2 inhibitors reduce the relative risk of HF hospitalizations by 27%–39% compared with a placebo. 28 Better clinical outcomes are thought to be a result of the underlying mechanisms, which include positive effects on heart remodeling and function.
Regardless of diabetes status, empagliflozin has been demonstrated to lower the risk of cardiovascular death and HF hospitalization in patients with HF with a reduced ejection fraction. 29 In individuals with T2D and diabetic nephropathy, canagliflozin has been proven to decrease the progression of renal disease and to lower the risk of significant cardiovascular events. A combination of SGLT1 and SGLT2 inhibitors called sotagliflozin has demonstrated potential in lowering events linked to HF. In adults with HF or T2D, chronic kidney disease, and other cardiovascular risk factors, sotagliflozin dramatically decreased the composite endpoint of cardiovascular death, HF hospitalization, and urgent HF visits in clinical trials. 27
In summary, by improving efficacy and decreasing adverse effects, these therapeutic advancements highlight the importance of customizing cardiovascular therapy to each patient’s unique profile. By incorporating targeted medicines into standard clinical practice, cardiovascular health outcomes could be greatly improved as our understanding of molecular pathways and patient-specific factors deepens.
Innovative methods of drug delivery
Drug delivery system developments have greatly improved the management of cardiovascular conditions, especially atherosclerosis. Novel platforms, such as biodegradable stents and carriers based on nanotechnology, have been created to increase treatment efficacy while reducing side effects.
Nanotechnology
This technique improves treatment efficacy and lowers systemic side effects by precisely delivering therapeutic chemicals to atherosclerotic areas. Targeted intervention in atherosclerotic plaques is made possible by engineering nanoparticles to contain medications, genes, or imaging agents. For example, platelet membrane-coated nanoparticles and other biomimetic nanodrug delivery systems have been developed to efficiently target plaques and have anti-inflammatory and antiangiogenic qualities that improve plaque stability. 30 The effectiveness of drug delivery via nanoparticles is strongly influenced by the shape of atherosclerotic plaques. According to previous studies, plaques with longer shoulder lengths may enhance particle adherence, whereas those with higher degrees of stenosis may decrease nanoparticle deposition. 30 Understanding these morphological effects is essential for optimizing nanoparticle design and enhancing therapeutic results.
Biodegradable stents
A prospective substitute for permanent metallic stents, biodegradable stents provide scaffolding to maintain the channel temporarily as it heals and then progressively breaks down. These stents frequently have biodegradable polymers such as poly-L-lactic acid (PLLA) implanted in them, along with antiproliferative medications such as sirolimus. This design lowers the danger of in-stent restenosis by preventing smooth muscle cell growth and enabling controlled medication release. 31
One of the latest innovations is the application of bioresorbable materials, which change with time and return the artery to its normal mobility. For example, the DynamX bioadaptor provides dynamic support while acting first like a traditional stent and then progressively restoring the artery’s normal functions. Clinical studies have shown that, in comparison with conventional stents, these devices are linked to a decreased incidence of heart attacks and the need for repeat treatments. 32 The rate at which the polymer coating degrades is crucial to the kinetics of medication release. The biocompatibility and favorable degradation characteristics of polymers such as poly lactic-co-glycolic acid and PLLA make them widely employed. Research indicates that the drug release rate can be adjusted to suit particular therapeutic requirements based on the molecular weight, content, and crystallinity of these polymers. 31 In summary, the treatment of atherosclerosis has advanced significantly with the use of biodegradable materials and nanotechnology in drug delivery systems. By combining controlled medication release with targeted therapy, these cutting-edge methods enhance patient results while reducing the risks associated with conventional therapies. Clinical studies and ongoing research are helping to improve these technologies, opening the door for a wider range of cardiovascular medical applications.
Wearable technology and telemedicine
Cardiovascular health care has undergone substantial transformation owing to the combination of wearable technology and telemedicine, which has produced creative approaches to patient management and monitoring.
Wearable technology
Smartwatches and fitness trackers are examples of modern wearable technology that have sophisticated sensors that can monitor a number of physiological indicators, such as blood pressure, heart rate, and ECG readings. Continuous health monitoring is made possible by these devices, which provide patients and health care professionals with real-time data and allow for the early detection of abnormalities such as arrhythmias. 33
To help detect atrial fibrillation early, the Apple Watch Series 10 has features including ECG monitoring and warnings of unusual heart rhythms. Analogously, the Samsung Galaxy Watch7 offers a wide range of health tracking features, such as ECG and blood pressure monitoring, which improve remote patient care. These wearables not only empower individuals to manage their health but also provide clinicians with valuable data for informed decision-making. However, issues such as device accuracy, data protection, and clinical workflow integration still exist and need constant attention. 34
Telemedicine
Telemedicine has become more popular as a result of the COVID-19 epidemic, which has changed how cardiac care is provided, particularly in underserved and distant areas. By eliminating the need for in-person visits and the related travel burdens, telehealth services have increased access to cardiovascular consultations, diagnostics, and rehabilitation. 35 For example, Australia’s quick adoption of telehealth services during the pandemic guaranteed the continuation of cardiac rehabilitation programs, enabling patients in isolated locations to receive critical care from a distance. This change demonstrated the potential of telemedicine to reduce health care gaps in remote regions while preserving patient participation during trying times. The widespread implementation of telehealth solutions is hindered by challenges such as payment rules, technological infrastructure restrictions, and patient disparities in digital literacy, despite these developments. 36
In summary, enhancing cardiovascular health outcomes may be possible with the combined application of wearable technologies and telemedicine. When combined with telemedicine systems, the constant data streams of wearable technology allow prompt, individualized medical solutions. Proactive disease management, early problem identification, and customized treatment approaches are made possible by this combination, which eventually improves patient outcomes and lowers health care expenses. As these technologies develop further, resolving current issues will be essential to achieving their full promise in revolutionizing cardiovascular care. Although, therapeutic advancements are influencing contemporary cardiovascular treatment, proactive prevention is still vital; the next section outlines how new digital tools are empowering preventive strategies.
Preventive Strategies Employing Cutting-Edge Tools
Cardiovascular health prevention techniques have been completely transformed by the combination of wearable technology and mobile health applications. By providing individualized interventions and real-time monitoring, these cutting-edge tools enable people to take charge of their heart health.
Mobile health applications
Cardiovascular health is now greatly enhanced by mobile health applications. Wearable technology is effortlessly integrated with apps such as MyFitnessPal and Apple Health, allowing users to track cardiovascular risk factors, food intake, and physical activity. By offering tailored feedback, these platforms promote self-awareness and healthier lifestyle choices. In these apps, gamification has become a powerful tool for increasing user engagement and maintaining long-term adherence to healthy behaviors. Challenges, prizes, and progress tracking are examples of game-like elements that encourage people to reach their health objectives. Gamified health applications have been shown to dramatically increase physical activity levels and positively impact cardiometabolic risk variables in persons at risk for CVD, according to a systematic review and meta-analysis. 37
Wearable technology and mobile health apps working together have the potential to improve cardiovascular health prevention tactics. These tools can support long-term lifestyle changes and early identification of any problem by offering real-time data and tailored feedback. Future advancements should concentrate on enhancing user involvement, guaranteeing data precision, and incorporating these technologies into standard clinical procedures to optimize their preventive capabilities.
Behavioral interventions driven by AI
Customizing health suggestions has become a game-changer owing to AI, especially in the context of AI-driven behavioral therapies. These systems evaluate personal information to customize health recommendations, improving the efficacy of cardiovascular health prevention measures. Chatbots driven by AI are leading in this customization, providing real-time assistance for behaviors such as weight control and quitting smoking. Through interactive discussions, these chatbots offer consumers personalized guidance and ongoing encouragement. While highlighting the effectiveness of AI chatbots in encouraging healthy lifestyles, such as quitting smoking and losing weight, a comprehensive study also revealed conflicting findings about their viability and acceptance. 38
In addition to providing behavioral assistance, digital platforms use AI to evaluate user data, which maximizes medication adherence and lifestyle changes. AI-powered systems, for example, can track patient data to forecast health occurrences and suggest prompt interventions. According to a previous study, 39 adults with hypertension experience a significant drop in blood pressure after receiving accurate lifestyle advice via an AI-based digital health intervention.
The use of AI in health interventions provides scalable solutions accessible via a range of platforms and devices, including social media and smartphones. By making individualized health suggestions accessible to a wide range of people, this accessibility may help reduce health inequities. However, maintaining user trust and involvement still presents difficulties. The acceptance and usefulness of AI chatbots have been the subject of conflicting research, which emphasizes the necessity of user-centered design and thorough validation. 38
In summary, AI-driven behavioral therapies have the potential to revolutionize cardiovascular health by offering individualized, real-time support for drug adherence and lifestyle modifications. To fully achieve the potential of AI in preventive health measures and handle current problems, ongoing research and development are necessary. In addition to prevention, advancements in regenerative medicine and big data analytics, which are discussed in the next section, define the future of cardiovascular health care.
Upcoming Frontiers and Prospects
Combining predictive analytics and big data
By making it possible to identify at-risk individuals and optimize care routes, the combination of big data and predictive analytics is transforming cardiovascular health. Large datasets, including patient histories, real-time physiological data, and genomic information, have been produced as a result of the widespread use of wearable technology and EHRs. These intricate datasets can be analyzed via sophisticated ML algorithms, which can find patterns and connections that conventional statistical techniques miss. For example, by evaluating EHR data, models have been created to predict HF survival, enabling early interventions and individualized treatment regimens. 40
Genetic predispositions to CVDs are better understood because of collaborative efforts such as the U.K. Biobank. Researchers have discovered uncommon variations linked to cardiometabolic characteristics and diseases by examining genetic data from sizable populations. The relevance of genetic variables in disease development was highlighted by a study that involved 200,000 participants from the U.K. Biobank and reported 57 gene-based connections with different cardiometabolic diseases. 41 These discoveries open the door for precision medical techniques, in which genetic data inform customized preventative and therapeutic plans.
There are chances to improve cardiovascular care through the integration of big data from various sources, such as wearable technology, genomics, and EHRs. To properly utilize predictive analytics in this area, however, issues such as data integration, quality control, and patient privacy need to be resolved. These strategies are being improved by ongoing research and technology developments to increase patient outcomes via data-driven, individualized health care solutions.
Therapeutic regeneration and gene editing
The treatment of cardiovascular disorders is being completely transformed by developments in gene editing and regenerative therapies, which may provide treatments for illnesses that were previously thought to be incurable.
CRISPR-Cas9
To treat monogenic CVDs, including hypertrophic cardiomyopathy (HCM), the CRISPR-Cas9 system has become a potent tool for precise genetic changes. Gene mutations, such as those in myosin-binding protein C3 (MYBPC3), are frequently the cause of HCM. To correct these mutations, recent research has shown that in vivo genome editing is feasible. For example, Nie et al. corrected a pathogenic MYBPC3 mutation in a rat model via CRISPR–Cas9–mediated homology-directed repair, which led to the restoration of protein production and normalization of heart function. 42 Similarly, Pavlova et al. used CRISPR-Cas9 to introduce a particular myosin heavy chain 7 mutation into induced pluripotent stem cells (iPSCs). 43 The pathogenicity of the variant was confirmed when the cells differentiated into CMs and recapitulated HCM symptoms. 43
Stem cell therapy
To heal cardiac damage, especially after an infarction, regenerative medicine uses stem cell technology. The capacity of iPSCs to develop into multiple cardiac cell types, such as cardiomyocytes, endothelial cells, and smooth muscle cells, has attracted interest. Transplanting these cells may help restore heart function. The translational potential of this strategy was highlighted by Ye et al.’s finding that massive cardiac muscle patches made from human iPSC-derived cardiac cells enhanced MI recovery in pig models. 44 Additionally, Zimmermann and associates created implantable patches made of iPSC-derived beating heart muscle. In both preclinical models and early human applications, these patches improved heart function when applied to injured myocardium by integrating with host tissue. 45
Even with these encouraging advancements, several challenges still exist. Delivering gene-edited components safely and effectively is still a major challenge. To enable targeted delivery of CRISPR-Cas9 ribonucleoproteins, novel techniques such as focused ultrasound in conjunction with microbubbles are being investigated. This could improve accuracy and reduce off-target effects. 46 Concerns about cell survival, integration, and possible immunogenicity must be addressed for stem cell treatments. Optimizing scaffold materials, improving cell differentiation techniques, and guaranteeing the functional maturation of transplanted cells are the main areas of ongoing study.
In summary, combining stem cell-based regenerative therapies with gene editing is promising for the treatment of cardiovascular disorders. For these cutting-edge technologies to completely realize their therapeutic potential and overcome current challenges, more interdisciplinary research and clinical translation are needed. As these promising new areas develop, addressing the associated challenges and ethical implications becomes essential to ensure equitable and responsible implementation, as discussed next.
Challenges and Ethical Issues
There are many challenges to overcome when cutting-edge technologies are integrated into cardiovascular health care, especially concerning accessibility and ethical issues. One major problem is that these technologies are expensive, which frequently prevents them from being used in environments with limited resources. Technologies such as photoacoustic computed tomography, for example, have significant costs associated with optical sources, ultrasonic detectors, and data collection systems, despite providing improved imaging capabilities. In areas with limited resources, these expenses present challenges for broad adoption. 47
The creation of inexpensive hardware solutions and the application of information and communication technology are two initiatives aimed at reducing these budgetary barriers. These strategies seek to improve health care access in underserved areas by increasing the affordability and scalability of medical devices and services. 48 However, careful consideration of the particular difficulties faced by low-resource settings is necessary for the successful implementation of these solutions.
Ethical concerns are also raised by the application of AI in health care, mainly in relation to algorithmic bias and transparency. Unfair treatment outcomes could result from AI systems trained on biased datasets, which would reinforce current inequities in health care delivery. To prevent health disparities from worsening, it is crucial to ensure that AI applications are created and used fairly and responsibly.
To overcome these challenges, strong legislative frameworks that give patient privacy, data security, and fair access to cutting-edge medical technology first priority must be established. Policymakers, health care professionals, and technology developers must work together to implement regulations that uphold people’s rights and encourage cardiovascular care innovation. Strict data protection laws must be upheld, AI algorithms must be made more transparent, and affordable solutions must be accessible to all groups, regardless of their financial situation.
The potential of biomarkers, imaging technology, and digital tools to improve cardiovascular health must be properly managed to overcome ethical and financial constraints. By taking proactive measures to address these issues, the medical community can strive toward a more ethical and inclusive use of technology in cardiovascular care. To effectively utilize these advancements, future research must not only address these challenges but also further improve the technologies, as highlighted in the following section.
Future Directions
The diagnosis and treatment of CVD have been greatly improved by the combination of biomarkers, AI-driven imaging, and digital health advancements (Table 1). There are still several issues, however, which call for more investigations and improvements. Future initiatives should concentrate on making these technologies more affordable and accessible. To guarantee clinical accuracy and reduce algorithmic biases, AI-driven diagnostics need to undergo a thorough validation process. Furthermore, further research should be conducted on multiomics techniques to find new biomarkers that enhance precision medicine tactics for managing CVDs.
Emerging Trends in Cardiovascular Health Care: Biomarkers, AI-Driven Imaging, and Digital Interventions
This table bring together landmark studies from various countries that showcases advancements in cardiovascular health care in three areas-biomarkers, AI-driven imaging, and digital tools. It summarizes research involving soluble ST2, galectin-3, and high-sensitivity troponins, along with advancements in cardiac MRI, 3D/4D echocardiography, and wearable ECG monitoring. The table also includes studies on digital health interventions and novel therapeutic platforms such as gene editing and stem cell therapies. By presenting each study’s focus and findings, this table provides a concise yet comprehensive overview of the technological advances driving a transition from conventional treatment models to personalized, data-informed cardiovascular care. AI, artificial intelligence; MI, myocardial infarction; ECG, electrocardiogram; CVD, cardiovascular disease; CAD, coronary artery disease; CMR, cardiac magnetic resonance; MRI, magnetic resonance imaging; HF, heart failure.
Progress in personalized medicine via gene editing and regenerative medicine is another exciting area. Treatment for genetic CVDs could be revolutionized by technologies such as induced iPSCs and CRISPR-Cas9. However, before these methods are used in clinical settings, their safety, ethical issues, and long-term effectiveness need to be thoroughly studied. Furthermore, risk assessment and therapy customization may undergo a revolution with the incorporation of big data analytics and predictive modeling into EHRs.
Early intervention and ongoing patient monitoring are anticipated to be greatly aided by wearable technologies and telemedicine systems. To optimize clinical impact, future innovations should prioritize enhancing data accuracy, interoperability, and real-time patient involvement. Furthermore, the use of drug delivery systems based on nanotechnology and biodegradable stents offers a special chance to improve focused therapy with few adverse effects.
Conclusions
Cardiovascular care is being revolutionized by the combination of biomarkers, AI-driven imaging, and digital health technologies, which allow for earlier diagnosis, more precise therapy, and individualized patient management. However, addressing challenges related to cost-effectiveness, accessibility, and ethical considerations is essential to maximize their global impact. To guarantee that new technologies are smoothly incorporated into standard clinical practice and, eventually, improve cardiovascular health outcomes globally, future research should place a strong emphasis on interdisciplinary collaboration.
Data Sharing Statement
No datasets were generated or analyzed during the current study.
Footnotes
Authors’ Contributions
Conceptualization: A.G. and V.G.; Data curation: A.G., V.G., and A.O.; Resources: A.G., V.G., and A.O.; Supervision: A.G., V.G.; Investigation: A.G., V.G., and A.O.; Visualization: A.G. and V.G.; Validation: A.G., V.G., and A.O.; Roles/Writing—original draft: A.G., V.G., and A.O.; and Writing—review and editing: A.G., V.G., and A.O. All authors have read and approved the final version of the article submitted to the journal.
Author Disclosure Statement
Nothing to disclose.
Funding Information
This review did not receive any grant from funding agencies in the public, commercial, or not-for-profit sectors.